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Chapter I
 
Introduction
 
1.1 Forward 
The impetu for thi study re uIt from activiti both personal and profe ional. 
Rationally it i ea y to see why the Crotallus atrox or We tern diamondback rattle nake 
has the highest rate of envenomation. Thi nake i actively hunted each year at 
numerous rattlesnake roundups. More rattlesnak are kept in captivity by both amateur 
and profes ional herpetologist, which could lead to more bite. However, from my 
personal experience as an outdoor adventure in tructor and avid outdoorsman I encounter 
mostly Agkistrodon contortrix contortrix snakes, more commonly known a the Southern 
copperhead, while in the out of doors. 
After doing an initial literature search it was clear that envenomations from 
rattlesnakes were more substantially re earched while envenomations from copperheads 
were not. It was also Clear, with re pect to envenomation, th copp rhead produced the 
most reported bites each year, with the xception of the rattle nake. From phon' 
inquiries to the Oklahoma Poison Control Center, the copperhead in Northea t Oklahoma 
had the highe t incidence of envenomation (per onal communication with M . Lee 
McGoodwin). The e facts lead me to que tion why there ha not been a more ub tantial 
body of work for this type of envenomation. 
On closer examination I learned of the newe t approved treatment available for 
snake envenomation. This newly approved antivenin is manufactured by ProTheric Inc, 
Nashville TN, under the brand name CroFab™. Although it i not manufactured with 
copperhead venom specifically in mind the EDso for Agkistrodon contortrix contortrix is 
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4mg roFab™/rng venom, a report d in th product insert 1 . In clinical term it takes 
4mg of CroFab™ for eery Img of copperh ad nom to pro id 100% prot ction for 
one half of tho e ani mals tested from death wi th in 48 hour . 
1.2 Ba.ckground 
There are approximately 120 specie of nake that are nati e to the United States. 
Of these. about 17% have venom that i hannful to humans. Th e snake all fall into the 
category of pit vipers, with the exception of th coraL nak. Venomous nakes have 
been identified in every state except, Alaska Maine. and Hawaii (2). Venomous snakes 
native to Oklahoma include the copperhead. prairie rattle nake, timber rattle nake. 
western cottonmouth, western diamondback rattle nake, we tern mas asauga rattl.e nake. 
and the pygmy rattlesnake, all of which are in the family Viperidae ubfamiJy CrotaUane. 
The subfamily Crotaliane includes the genu of Agkistrodon (copperhead and 
cottonmouth), Crotalus (rattlesnakes), and Sistrurus (rna asauga and pygmy 
rattlesnake) (3). Each year in the United State there are approximately 7.000 to 8.000 
bites by venomous snakes with 5 or 6 related death (2,4,5). Death typically occur in 
children or the elderly. Death may al 0 be a ociated to tho e individual who do not 
seek treatment or if treatment is administered in an in ufficient amount of time to rever e 
the effects of the venom. Most, if not all, bite occur on extremitie as a deliberate 
attempt to handle the snake. or as an unfortunate accident of stepping directly on a nake 
(2,4,5). Bites occur most often in the period of late pring to early fall when the nakes 
are most active and people are most often in the out of door (5). Of the reported 
snakebites from venomous snakes, 25% are from the copperhead snake. This i more than 
any other venomous snake, with the exception oftbe rattlesnake (4,5). 
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1.3 Venom Components 
Snake venom i a specialized cocktail that includes enzyme and tox.ins which 
have evolved to aid the snake in the capture and dige tion of prey (6). The re ulting 
actions of these enzyme and to ins can ha profound effects on both prey animals and 
humans who are unfortunate enough to be bitten. Of thi cocktail, neurotoins are of 
particular importance, producing paralysis of keJeta·1 mu de (6). Neurotoxins can be 
classified according to their site of action within the nervou y tern, such a pre-synaptic 
or post-synaptic (2,6). Pre-synaptic toxin have varying action or activities of 
phospholipase A2 and have been identified in the Viperidae family as well as others. The 
action of phospholipase A2 (PLA2), which is the most studied component of snake 
venoms, is associated with the blockage of release of acetylcholine (ACh), the major 
neurotransmitter in muscle end plates. The inhibition of ACh release at somatic mu de 
results in paralysis of bulbar and ocular muscle , as well as paralysis of respiratory 
muscles, which could cause death (2,4,7,8). Po t-synaptic neurotoxin aL 0 act on 
muscle, however their effect i to antagonize the nicotinic receptor in k I.etal rnu cl . 
Post-synaptic neurotoxin have only been identified in two fam.ilie of venomou nake, 
Elapidae and Hydrophiidae, neither of which are native to the United tates (6). 
In studies with dogs, phospholipase A2 is hown to produce a harp fall in mean 
arterial blood pressure along with a dramatic rise in pul e pre ure. Effects al 0 included, 
after a lethal dose of venom (0.5-1.0 mg/kg i.v.), change in EEG or ECG and heart rate, 
prolonged apnea, with arterial pre sure remaining low until re piratory arrest (7). 
Agkistrodon venom PLA2 (Ag PLA2) alters mitochondrial respiration and 
phosphorylation. At low concentrations, Ag PLA2 increased mitochondrial respiration in 
the ab ence of a pho phat . acceptor. At high cone ntratioo , Ag PLA2 cau ed evere 
inhibition of electron transport, and intermediat concentration of Ag PLA2 produced a 
decline in respiration in which ADP acted a an inhibitor (7). High v nom concentration 
also block axonal conduction in axon of lob ter leg and al 0 the giant axon of quid 
(7). This conduction blockage is attributed to the enzymatic hydrolysis of the acyl bood 
at the C2 carbon of cell membrane phospholipid (8). Venom PLA2 ha also been 
associated with increased cell membrane permeability, e pecially platelet membranes (7). 
1.4 Systemic Effects of Venom 
Humans have varying systemic effects as the result of nake envenomation. 
These effects depend on a number of factors, which include the species of soak! , quantity 
of venom injected, and the time between envenomation and the admini tration of an 
appropriate medical treatment (2,4,5). Clinical effects of snake envenomation may range 
from mild to severe, again depending on the factors described above. However, effect 
are also dependent on the size of the person bitten with maHer per on howing more 
profound effects because of receiving a larger do e relative to body ize (4,5). y ternic 
effects include nausea, vomiting, perioral pare the ia, tingling of fingertip and toe , 
myokymia, lethargy, and general weakne s. The e yrnptoms generally occur early after 
an envenomation (2-5). More severe effect occur after a longer period of time, and often 
include hypotension, tachypenea, respiratory distre , severe tachycardia, and altered 
sensorium (2). Components from venoms may al 0 cause an increase in the permeability 
of capillaries, which results in extravasation of electrolyte , albumin, and red cells into 
the bite site. This process may also rarely occur in the lungs, myocardium, kidneys, 
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periton urn and central nervou y tern. 2). In mor enou n enomations, renal failure 
may occur from hypoten ion 26). 
Generally the bite of the copperhead nake i thought to be mild or benign in 
clinical significance. The traditional nakebite e erity coring y tern u ed to grade an 
envenomation is the major factor from which thi stem . The coring y tern i ba ed on 
a combination of local and systernk effects, which weighted' toward y temie 
symptoms and tjssue necrosi (4). Table 1 hows the traditional nakebite severity 
scoring scale (4). 
Table 1. Traditional snakebite severity coring scale 
, Severity (Grade) Manjfestations Amou nt of antivenin 
recommended (ACP)
 
No Envenomation (0) Local or systemic signs absent 0
 
Minimal (1) Local swelling 2-4 vial
 
Absence of systemic signs
 
Normal laboratory findings
 
Moderate (lI) Swelling extending past bite ite 5-9 vial
 
(6-12 in)
 
~I ystemic ign or symptom
 
Abnormallaboratorv findings
 
Severe (III) I Marked (> L2 in) welling 10-15 vial
 
I Ti ue 10 s 
Multiple or evere y terni 
symptom' immediate y t mi 
signs, rapid progression of 
symptoms 
, Very Severe (VI) Rapid development of local >1.5 vials 
reaction 
cchymosi ,IJ cro is, blebs, 
blisters 
SweHing severe enough to 
obstruct venous or arterial flow, 
swelling may involve ip ilateral 
trunk 
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Copp rh ad nak< bit rarely exhibit the type of yrnptom. A a result, the highest 
grade a copperhead en enomation can r ceive i II (4 5). 
The most significant recent tudy on copperhead nvenomations was conducted in 
West Vi.rgina during the period from January 1, 1995 to eptember 30, ] 9 . [n this 
study ninety-two patients were identifi d that met the criteria for inclusion in thi study 
(4). Inclusion criteria were that the nake is po itively or probabLy identified a a 
copperhead. An identification wa con idered to b po itive if the snake wa brought in 
to the emergency department or killed on site and identified by at least on person tn 
addition to the person bitten for example, poLice, emergency medical ervice per onnel or 
other aduLt presumed to be reliable. A local scoring sy tern was developed for this study 
and is shown in Table 2 (4). 
Table 2. Local effect scoring system for copperhead envenomations 
Score 0 I 2 3 4 
Local Effect 
Pain None Present Pain pre ent, Pain present, Pain present, Pain pre ent, 
no pain APAP or oral nonopi te· opiate 
management NA to parenteral allalge ic 
needed uffi ient analge ic requir d for> 
required 24 hI' 
Swelling None Pre ent	 Confined lnvolve [nvolve S; one Extends 
within 7.5 ern greater than or half of affi cted b yond 
of bite site equal to one extremity affected 
half of affected extT mity 
extremity 
Ecchymosis None Pre ent Confined Involves Extends
within 7.5 ern greater than or Involves S; one beyond
of bite ite equal to one half of affected 
affectedhalf of affected extremity 
extremity
extremity 
Time from No Progression > 8 hr >4 hI'S; 8 hI' >lhr~4hr S; 1hI' 
bite to reach 
full swelJjng 
or l'Cchymo!>1s 
APAP, acetamino phen: NSAID , non teriodial anti-inflammatory drug * For exam pIe, 
ketorolac butorphanol, nalbuphine, or buprenorphine. 
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Thi new cormg t m u differ nt rit ria than the traditional snakebite 
everity grading scale. It i different in the fact that pain play a major role in scoring. 
Both scales use a 0-4 cale with a core of 0 having no apparent effects on the patient and 
4 being the most severe effect expected. The r ults in thi study how that 1/3 of tho e 
patients with copperhead nakebite had a clinically ignificant local effect with an 
average score of 3.5 (4). The majority of patient bitten wer admitted to the hospital. 
These results would tend to sugge t that th bite of th copp rhead is not as benign a 
once thought. 
1.5 Early Use of Fab Fragments 
The first antivenin for human use was for the treatment of cobra envenomation 
(7). The antivenin was prepared using unrefmed horse serum and frequently produced 
anaphylaxis, hypotensive crises, and other numerous unwanted side effects (9,10).n 
1954 Wyeth Laboratories, Philadelphia, Pa, introduced Antivenin (Crotalidae) 
Polyvalent (ACP), which until recently, wa the only approv d treatment available for 
snake envenomations in the United State. This treatment i often as ociated with an 
immediate adverse reaction rate as high as 56% and a delayed adver e reaction of up to 
75% (6,5,11). This rate of adverse reaction had practitioner debating on its effectivene 
and use. Today mo t antivenins are either partially purified immunogloublin 0 (lgO) a 
produced in the United States or antigen binding fragments (Fab2) a produced in Europe 
and other parts of the world (5). Since humans have such adverse reactions to hor e sera 
attempts have been made to produce antivenin from both rabbit and goats. The results 
from these attempts are encouraging (5,12,13). 
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The ad er e reaction of A Pare w 11 document d however they are mostly 
from retrospecti e tudies. In contra t the tudie conducted for adv r reaction to a 
new treatment available, CroFab™, for nake en enomation are more prospective. A 
rate of incidence of 14.3% (6 out of 42 patien ) for acute reaction was r ported for 
CroFab™ in contrast to acute reaction rate for ACP of a high as 56% (9,10). Al 0 
reported were the rates of serum sickne for both ACP and the newly approved 
CroFab™, which was 75% and 16% re pectively.lt should be noted that CroFab™ has 
not been shown to produce anaphylaxis. However, experience with CroFab™ i too 
limited to say whether or not anaphylaxi will occur. (9). 
In 1985 RusseU et. at. demonstrated that an ovine Fab antivenin could be prepared 
by using affinity chromatography (10). Briefly, gel affinity chromatography was used to 
identify and purify antibodies to the venom of four different species of rattle nake. 
These antivenins were evaluated for neutralizing deleterious effects such as cytolytic, 
hernmorhagic, plateLet aggregating and Lethality. Re ults from thi tudy wer compared 
to those obtained with ACP using the same t chnique . Thi new antivenin wa hown to 
be more efficacious in neutralizing these delet dous effects while not exhibiting any 
evidence of producing anaphylaxis or anaphy'lactic reaction in animal en itized to 
horse serum (9,12). 
The use of sheep sera to produce Fab fragment is not new, with the first recorded 
use of Fab fragment antibodie for digoxin (9-11). This antibody was fir t developed in 
1967 as the digoxin immunoassay, and in 1971 digoxin antibodies were fir t used to treat 
digoxin toxicity in dogs. The first human patient to receive digoxin specific Fab 
fragments was in 1976 (9). A Fab fragment that is antigen specific can be produced. 
relatively qujckly and easily for aJmo t any toxin. The proc imple;fir t an animal 
is hyperimrnunized with th de ired antig n thi may b a goat, sheep, rabbit or another 
animal that is suitable); the animal i then bled, the era te ted for antibodie specific to 
the antigen, then the antibodies ar purified. Th antibodi 5 are then dige ted with 
papain, which yields two antigen binding fragmen (Fab) and on cry taUine fragment 
(Fc) each with a molecular weight of -5 000 Da. The Fab i purified by gel affinity 
chromatography. Another type of antibody molecule, which contains 2 Fab fragment 
(Fab2), can also be made from the original, also without the Fc, portion by dige ting it 
with pepsin. This molecule can also be effective in neutralizing toxins (1,10,11). 
1.6 Treatment Using Fab Fragments 
Although treatment for digoxin poisoning has been avai labIe since the early 
1970's it was not until recent time that a treatment for snake envenomation utilizing a 
Fab fragment was available. In 1997 two reports were published each claiming to be the 
first clinical experience with the u e of Fab fragment to treat nak envenomation. One 
report was published in the Journal of Internal Medicine. Thi study was u ed to 
determine the response of a Fab antiv nin again t Vip r berus, which i a viper 
indigenous to parts of Europe (14). The pecifie Fab fragment produced to neutralize the 
effects of V. berus envenomation proved to be almo t ten time more effective on a 
weight-to-weight basis as compared to a more traditional equine antivenin (14). Thi 
study took place in the period of 1991-1997 with Swedish patient who were re ponding 
poorly to traditional treatment. The objective of this tudy was to determine the clinical 
efficacy and incidence of adverse reactions associated with the Fab fragment. Re ults of 
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thi tudy bo that the efflcacy of the tr atm nt i comparable to tho with the 
traditional treatment, however at a much smaller do ofantibodie (14). 
The econd report claiming to be th fir t clinical exp rience with a specific Fab 
fragment for snake envenomation as publi h d in Am rican Journal of Tropical 
Medicine and Hygiene in 1997 (15). Howev r thi report u es a monospecific antivenin 
for the treatment of E. ocellatus or carpet viper found in Northern Nigeria, which is 
responsible for greater than 95% of the envenomation in the region (15). For thi study 
a comparison of efficacy between the monospecific Fab antivenin (EchiTabTM) and 
Institute Pasture Serum Africa antivenorn (lpser) wa described. Re ults from this study 
suggest that 0.5 g (one vial) of the EcbjTab™ produce the arne response as 2.12 g (fOUf 
ampules) of Tpser ( 15). 
Regardless of which study is first, results from reports such as these sugge t that 
monospecific ovine Fab fragment antibodie are a effective at neutralizing the effects of 
snake envenomation as more traditional antivenin of equine origin. R 'ult al 0 uggest 
that these antibodies are at least a safe, if not more so, than antibodie derived from 
horse sera. Potential advantages and explanation for this could be b cau e equin 
versions of antivenins contain large amount of heavily glyco ylated IgG. It is thi 
glycosylated Fc portion of the IgG molecule that leads to greater antigenicity (14). 
Unlike intact IgG, Fab fragments only have a single binding ite and do not form 
cro s-linked immune complexes. Fab fragment exhibit fa ter kinetics due to th smaller 
size, which allows for a larger volume of di tribution than conventional antivenins. 
Finally, the purity of the Fab fragment is much higher due to the affinity chromatography 
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step in their production. However the shorter half-life of Fab fragments i a potential 
disadvantage (14). 
1.7 Production of CroFab™ 
With thi knowledge in hand researchers th n began a tudy in which heep were 
used to produce antibodie to particular venoms of clinical importance to North America. 
To produce this antibody/antivenin, four different flocks of heep were inoculated with 
one of four types of snake venoms native to the United State . Snake were cho en with 
particular criteria in mind: clinical importance in the U.S. and Northern Mexico, 
geographic range of the snake, genetic di imilarities of the venom, and cross­
antigeneicity with venoms from other clinically important crotalids (1,5,10). Snake 
chosen for study were Crotalus atrox (Western diamondback), C. adamanteu (Eastern 
diamondback), C. scutula/us scutulatus (Mojave rattlesnake) and Agkistrodon piscivorus 
(Eastern cottonmouth) (1,5,10). The sheep flocks were bled and each monospecific 
immunogloublin was precipitated with Na2 0 4 , redi olv d, and then dige ted with 
papain (5,6,10). The resultant Fab fragment wa th n u ed to determine its effectiveness 
in mice. In addition to the venoms used to inoculate the he p, ix other crotalid venoms 
were tested using this antivenin. Result from thi tudy how that the Fab antivenin was 
significantly more potent than the more traditional A P, not only again t the specific 
venom used to inoculate the sheep but it al 0 gay relatively good cros -protection from 
the additional venoms (5, I0). 
As a compari on, the more traditional ACP is also produced using venoms from 
four different snakes. However, only two of these nakes are native to North America 
with the other two native to South America. Also a contrast these four venoms are 
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injected into a ingle animal. The hor e i then bled and th anti-bodies coUected. The 
antivenin produced from thi proc not only contain IgG molecule but al 0 hor e era, 
which leads to the antigenicity of the antivenin. 
The technique of affinity chromatography was u ed in the production and in vivo 
analysis of CroFab™ with empha is on the EDso for the venom used. roFab was also 
tested in mice against venoms not used in it production (1,10). The EDso, for A. 
contortrix contortrix, the venom used in this report, was 4 mg CroFab™/ mg venom 
tested (l,10). 
The hypothesis for this tudy is there is antivenin venom binding, which can be 
analyzed using Size ,Exclusion-High £ressure (performance) 1iquid Chromatography 
(SE-HPLC). Thi.s is a technique that has allowed for fast and efficient purification and 
analysis of peptides based primarily on molecular mas (16-18). Another area where SE­
HPLC has proven useful is in the study of antibody-antigen (Ab-Ag) complex formation 
(19,21). Clinically SE-HPLC has been used to detect, identify and characterize table 
Ab-Ag complexes in studies of malaria, in ulin autoimmun disea e, cancer, and 
leukemia and lymphoma (19-21). The formation of table complexe in the ca e of A P 
with C. Qtrox venom has also been described (20,21). 
1.8 Use of SE-HPLC 
Size exclu ion liquid chromatography [s a term used to de cribe the 
chromatographic separation of molecules based on ize or mass (19-21). A mall volume 
of a solution containing the sample is injected and alJowed to interact with a column 
containing a material with pores, which are of comparable size to the molecules to be 
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separated. The mobile phase is pump d under pre ure through the column. The 
molecule' size determine how much interaction occur in the column. 
The basic principal of SE-HPL elution profile analy i u e are 1) elution time 
or volume, and 2) peak area or peak height (16 17,22). Th elution time or volume is 
related to the molecular mas of the molecule involved a d t rmined from a eries of 
standards. The injection volume and shape of the molecule al 0 influence the elution 
time, which could lead to non-ideal elution profiles. The peak area or height is related to 
the concentration of the components. Commercially available oftware, such as PeakFit 
(SPSS, Inc. Chicago, IL) is available for detecting multiple peak in an elution profile. 
Other methods for determining the peak height or area have also been described (22). 
The fundamental concept of SE-HPLC is that tb larger the molecule, the faster it 
will come out or elute, which makes the analysis of an elution profile relatively 
straightforward and simple. Other factors, be ide the ize of the molecule, such as the 
composition of the eluent or mobile phase, pH of the mobile pha e and the compo ition 
of the column may also influence at what point in the profile a molecule will elute 
Modem pre-packed columns contain small particl s 15 J.l.m or Ie which re ults in larger 
amounts of surface area with which molecule can interact. They can be afelyoperated 
up to a flow rate of ImUmin, which give run time of about 20 minute. Information 
from the various manufactures can help in determining the proper column needed for the 
application to produce the desired results. 
The fonnation of a high molecular weigh complex can be detemlined ju t by 
examining an elution profile. The appearance of a peak with elution time that are 
shorter than the antivenin or venom alone are indicative of complex formation (16,17,22).. 
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It is the appearanc of thi peak or tb lack of it which determin if ther has indeed 
been complex formation. 
Another con ideration when ana.lyzing a E-HPLC profile i resolution of the 
profile. Resolution in tbi ca e can be defin d as the d gree of eparation of adjacent 
peaks within an elution profile. Factor that influence re olution could include flow rate 
of the mobile phase, compo ition of the mobile phase, pH and the ize 'of the pore in tbe 
column. Flow rate of the mobile phase is important in that at a lower rate give the 
reactants more time to interact with each other and the column thu increasing resolution. 
Composition of the mobile phase and pH al 0 can affect re olution by denaturing or 
precipitating the reactants to the point where no peak are seen. Resolution may also be 
affected by pore size. For exampte, a column with mall pores would increase resolution 
for smaller motecules and decrease resolution for larger ones becau e of the smaller 
molecules ability to "get inside" or interact with the internal portion of the column. In 
contrast, a column with large pore allow for great r r olution of larger mole ule and 
decrease the resolution for smaller one. olumns are chosen depending on the ize of 
the molecule in question. If a column is cho en with the wrong pore size for the 
molecule in question, either too small or too large, a non-ideal elution profile will re ult. 
Help in choosing the correct column can be obtained from the variou manufacturer. 
1.9 Purpose of the Study 
The goal of this study is to determine if a stable high molecular weight complex is 
formed between CroFab™ and A. contortrix contortrix. This will be accomplished by 
injecting reaction mixtures a SE-HPLC column and the resulting elution profile analyzed. 
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To determine if th compl x form tion i d dependant variou concentration of
 
venom wi Il be u ed whit ke ping the cone ntration of anti enin con tant.
 
The pecific goal ofthi project are.
 
l) Determine if a high molecular eight compl x i form d.
 
2) Determine if complex formation i do e d pendent.
 
3) Determine an apparent ECso for the complex. The E 50 i defined as the effective
 
concentrations of venom where one half of reactive antivenin i bound to venom. 
4) Compare the apparent ECso to the r ported ED o. 
5) Determine ifCroFab™ exhibit any cro reactivity between enoms. 
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Chapter n
 
Materials and Methods
 
2.1 Experimental Design 
Venom will be added to a solution of roFab™, Img/mL final concentration at 
various concentrations between 0 and 1 mg/mL. Thi reacti.on mixtur will then be 
injected into a SE-HPLC column; typically the volume injected will'be 20 J.1L, with a 
flow rate of 1mL/min. As the reaction mixtur elutes it will then pas through a 
photodiode array detector and the resulting profile will be monitored at 280 nm using the 
Millennium software (Water, Milford MA). The resulting elution profiles will be 
corrected for baseline, and then normalized and integrated as described below. 
2.2 Instrumentation 
The SE-HPLC system consisted of a Waters (Milford MA) solvent debvery 
pump, a Waters universal chromatography injector (Model U6K), a Bio-Rad Silect 250-5 
(300 x 7.8mm) ize-exclusion column, and a Water 996 photodiode array d t ctor. 
Column temperature was 25° C (room temperature). Elution buffer wa 0.05 M sodium 
phosphate (pH 7.4) containing 0.05 M sodium chloride. The flow rate wa I mL/rnin. 
Absorbance of the eluate was monitored at 280 nrn. 
2.3 Antivenin, Venom, and Standards 
The Antivenin, CroFab™, was a generou gift from Suzanne Ward, director of 
product management for Protherics. Antivenin was rehydrated with elution buffer 
according to the instructions from the manufacturer, and then further purified u iog the 
SE-HPLC system. Approximately 500 JlL of a stock solution of antivenin (10 mg/mL) 
was injected into the SE-HPLC system and the major peak containing the Fab fragment. 
16
 
SigmaPlot (SPSS, Inc., Chicago IL). Each t of elution profile was aI 0 compared and 
adju ted for sample ize and concentration. 
2.6 Method of Analysis Using Elution Profiles 
Analysis of mixture containing antivenin and venom were based on methods 
described for antibody-antigen interactions u ing SE-HPLC (19,21). The e method 
were modified to fit this study. The basis of the analysis of reaction mixture is ba ed on 
the assumption that either the concentration of reactants and products in the mixtures are 
proportional to either peak area or peak heights from the chromatograms. This 
assumption has been used to determine antivenin-venom binding that occurs ba ed on 
equations derived from the law of mass action (19,21). 
The relationship of the elution profile area to component area i generalized by 
T=A+B+C, [I] 
where T is the total profile area and A, Band Care unreacted antivenin, unreacted venom 
and venom-antivenin complex area, resp ctively. The relation hip of total profile area to 
concentration of components can be generalized by, 
T =a' (Ao) + 13- (Bo), [2] 
where (Ao) and (Bo) are rng/mL antivenin and venom respectively, a and pare 
proportionality constants determined from a series of control mixtures and represent the 
slope of the linear equation for unreacted antivenin and venom control. Profile areas 
were normalized to 1 mglmL Ao by, 
Tnorm = (l + 13 (Bo)1 (Ao) [3] 
where Tnom1 is the normalized profile area. Normalized profile were produced by, 
Pnorm =(Pobs I Tobs) . Tnorm [4J 
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where Pnonn i th normaliz d profile, Pob i tb ob erved profil and Tob i the total area 
of the ob erved profile. Thi proc dure i u ful for normalizing data u ing other 
concentrations of reactants and for combining information from different et of reaction 
mixtures. 
2.7 ormalizatioD of Elution Profiles 
Variables, which may affect the elution profile, may includ injector malfunction 
or not injecting exactly 20 ~L, detector re pon e, and experimental error. U iog the 
procedure described above normalizes all profile . The result of the calculation produces 
a profile that is normalized to 1mg/mL antivenin. Figure I is a representative elution 
profile of the same reaction mixture before and after normalization. The conditions for 
the profile are Img/mL CroFab™ and I mg/mL copperhead venom. Plot A in figure 1 
are injections of the same reaction mixture ran at different times before any normalization 
has been performed. The figure shows the profile are not identical, with differences in 
the peak heights. Plot B in figure the arne reaction mixture profile after 
normalization has been performed. The plots are much closer to identical. 
Normalization not only takes into account the variable de cribed above, it al 0 allow 
the reaction mixtures from different experiments to be combined and compared on an 
equal basi. 
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Figure 1. Repre entative elution profile of a 1 mg/mL antivenin and I mg/mL venom 
reaction mixture. Plot A is the I sl and 2nd run of the ame reaction mixture before any 
normalization procedure. Plot B is the am elution profile after the nonnalization 
procedure has been performed. 
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2.8 Integration of Profile· 
Integration of elution profile is relati Iy straightforward and e y to p rform. 
On examination of the profile of th tandard it an be d termin d which of the r actant 
molecules would elute fir t, in thi ca e th anti enin, and any molecul det.ected b fore 
the expected time may be any complex form d. The re ultant profil ar then x.amin· d 
and time points are chosen for the integration t p. The sel ction of time point is critical 
to the process. If inappropriate time points are cho en orne complex may be mi cd and 
its area underestimated or too much area may be assign d to the complex. T i is also 
true for the antivenin with not enough or too much area a signed. For the integration st p 
in this study integration times were, 5 min to 7.5 min for complex formation, and 8 min 
to 10 min for the antivenin. The areas related to the e time points allow for optimal area 
of each component to be assigned. 
2.9 Synthesis of Null Profiles 
In order to determine if indeed there wa a high molecular weight complex 
formed or if there were any changes in profiles, null profile were needed. Null profiles 
are profiles expected if no reaction were to occur betwe n antivenin and venom. Null 
profiles can be synthesized by adding the profile of each venom and antivenin controls. 
2.10 Analysis of Cross Reactivity 
[n 1998 Steven et al (23) de cribed a method in which SE-HPLC was u ed for 
epitope mapping. In this method an antigen is incubated with two antibodie eparately 
and then with the same antibodies together. The resulting elution profile are then 
compared with that of a ynthetic null profile produced by adding the profiles of reaction 
mixtures containing the antibody and antigen with that of the third component, which has 
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been independently chromatographed. To evaluate the profile for epitop p cificity a 
difference or delta profile is then produced. Thi profil i th re ult of ubtracting the 
synthetic null profile from that of the reaction mixture that contain all component. 
A positive first peak in the delta profile indicate the increa ed formation of high 
molecular weight peaks. From thi increa ed complex formation it can be aid that the 
antibody recognizes spatially or tru.cturally different epitope on the 'urface of the 
antigen. In contrast, a negative fir t peak indicate a reduction in the fonnation of high 
molecular weight complexes. A reduction in high molecular weight complexe reveals 
binding specificities for overlapping or identical site (23). This method of epitope 
mapping was modified to fit this study. In contra t to epitope mapping the procedure was 
used to determine if the binding of antivenin to venom exhibited any cross reactivity 
between venoms, or if the antivenin has any residual reactivity for one venom after 
binding with another venom. 
To determine if there IS any cros reactivity b tween venom used in the 
manufacturing of CroFab™ and copperhead venom, a cro s reactivity tudy wa 
performed. This was accompli hed by initially incubating a reaction mixture containing 
either copperhead or rattlesnake venom with roFab™ for I hour at 37° . After the 
initial incubation period the reaction mixture was divided in half. An additional aliquot 
of elution buffer was added to one reaction mixture and an additional aliquot of the 
opposite venom was added to the other. Final concentrations were O.5-mg/mL for the 
venom and 1.0 mg/mL for CroFab™. Samples of reaction mixtures, typically 20 ~L, 
were injected into the column and the eluent monitored at 280nm. The information 
gathered was used to determine if the antivenin exhibited cross-reactivity between 
22 
venoms. Additionally, the data as u d to d termine if binding wa independent in 
nature. 
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Chapter In 
Result 
3.] Controls 
Repre entative elution profile of CroFab™, A. ontortrix ontotrix, and C. atrox 
are shown in figures 2, 3 and, 4. re p cti ely. Th e chromatograms r pr nt the 
controls at various concentrations u ed in thi tudy (Fig 5). Proportionality con tants a 
(antivenin), f31 (copperhead), and ~2 (rattle nake), wer calculated u ing data from figure 
5 using the linear equation for the slope of the line for total area of the chromatograms. 
Those proportionality constants were then used to nonnalize the profile of each mixture 
to I mglrnL ofCroFab™ by using the procedure de cribed under Material and Method. 
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3.2 CroFab™ v • Copperhead 
Figure 6 how a erie of normalized ynthetic null profiles of mixture of 
CroFab™ and copperhead venom. Plot A of figure 6 repr n the elution profile of a 
1mglmL CroFab™ control, a 1 mglmL copperh ad venom control, and a synthetic null 
profile of a reaction mixture of antivenin and copperhead enom at I mg/mL. Figure 6 
plot B is the synthetic null profile for each concentration of copperhead venom u ed for 
controls and is representative of no I' action taking place. Regions of the elution profile 
where integration was performed are also indicated on the plot. 
Figure 7 is normalized elution profile of reaction mixtures of antivenin and 
copperhead venom. Plot A in figure 7 represents a 1mglmL CroFab™ control and a 
reaction mixture containing 1mglmL CroFab™ and 1mg/mL copperhead venom. Figure 
7 plot B is representative of reaction mixtures of CroFab™ and copperhead at various 
concentrations. Evidence of complex formation is demon trated by the formation of a 
high molecular weight complex and the decrea e in the antivenin and venom component 
peaks with increasing venom concentration. Figure 7 plot B al 0 ugge ts that complex 
formation is dose dependant with complex area increasing with increa ing v nom 
concentration. Two major peaks designated cplx (complex) and cfab ( roFab™) ar 
seen. Areas of the elution profil.e where integration was performed are indicated on the 
plot. 
Figure 8 shows the integrated peak area for the areas chosen a a function of 
increasing venom concentration. Included are null complex, reaction complex (cplx), 
CroFab™ (cfab), the null CroFab™ area, and the total area of the profile. The graph is 
another indication of complex formation as well as confirming the dose respon e 
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relation hip of anti enin to nom. Th plot a1 0 demon trat ho djfferent data ts 
can be combined and pro id a graphical m an of e aluating r lati e r action 
component and compLex peak area. From the fit ofth data to a hyp rbolic function of 
Cplx = CpLxarea • (Veno) / (EC 0 + (V no)) [5] 
it was determjned that the apparent ECso for copperhead venom wa 0.05 mg venom / mg 
CroFab™ (R2 >.99, P <0.001, SE<O.OI). 
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Figure 7. Representative elution profiles of reaction mixtures. Plot A is the elution 
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3.3 CroFabT t' vs. Rattlesnake 
Because CroFab™ i not manufactur d with copp rh ad venom a compari on 
was performed with a venom that i used in it' manufacturing. C. atrox v nom wa the 
one chosen for this comparison. 
The elution profile shown in figure 9 show a ene of ynthetic null profile of 
mixtures of CroFab™ and rattle nake venom. Plot A of figure 9 repre ents a 1 mg/mL 
CroFab™ control, a I mg/mL rattle nake venom control, and a synthetic null profile of a 
reaction mixture between antivenin and rattle nake venom at 1 mglmL. The elution 
profiles shown in plot B of figure 9 are the synthetic null profile of I mg/mL antivenin 
and various concentration of rattlesnake venom. Region where integration was 
performed are also indicated on this plot. These plots repre ent the expected elution 
profile if no reaction were to take place between reactant . 
The elution profiles in figure 10 are profile of normalized reaction mixtures. Plot 
A represents the reaction mixture of antivenin and Img/mL rattle nake v nom. Plot B i 
the elution profiles seen with various concentrations of rattle nake venom while holding 
the antivenin con tant at I mg/mL. [ntegration time point are also included in this 
figure. 
As with copperhead venom evidence of complex formation i demon trated by 
the formation of high molecular weight complexes and the decrea e in the antiv nin and 
venom component peak with increasing venom concentration. Figure 10 plot B al 0 
suggests complex formation is dose dependant with complex area increasing with 
increasing venom concentration. 
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For analy i of profil r gion er cho en comparabl to th echo n for 
copperhead venom, with comple (cpl ,enom n) and roFab™ (cfab) region 
identified. The raw data obtained normalized to 1m mL CroFabT by u ing the 
procedure previou ly de cribed. 
Figure II shows the integrated profile ar a for region cho en a a function of 
increa ing venom concentration. Includ d are null cptx, cplx, null cfab, arid total profile 
area. The graph is further evidence of campi x formation a well as conflIllling the do e­
response relationship. From the fit of the data to a hyperbolic function, (equation [5]), an 
apparent ECso for rattle nake venom as det rmin d and i 0.04 mg rattle nake venom / 
mg CroFab™ (R2>.98, p<0.005, SE<O.O I). 
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Figure 9. Repre entative ynthetic null profil of roFab™ v. . atrox venom. Plot A 
repre ents CroFab™ alone, a 1 mg/mL venom control and a ynthetic null profile of a I 
mg/mL antiv nin-rattle nake venom mixture. Plot Bare th profile expect d if ther 
were no reaction or complex form doer th full range of concentration u ed. 
34
 
0.016 
Q,) 
en 
c: 
0 
0­
en 
Q,) 
~ 
.... 
0 
u 
Q,) 
U 
0 
0.012 
(J.008 
0.008 
0.012 
0.004 
0.000 
0.016 
Plot 
/ 
../ 
6 
Plot B 
:\ 
I . 
n 
J\ 
I \ 
II 
I I 
I I 
I \ 
I \J 
I 
/ 
/ 
8 
CroFab Only 
CroFab + en m (0.015 mg/m L 
roFab + en m (0.031 mg/mL 
roF b + n m (0.0 2 mg/mL) 
r "ab + V n m 0.125 mg/mL) 
ro"ab + en m(0.2 mg/mL) 
roFab + V nom 0.5 mg/m ) 
roFab + Yen m 1.0 mg/mL 
Time P iot U ed or IOlegrati 0". 
r ab nly 
r fa b + en m 1.0 mg/mL
-­
f\ 
I'\ 
\ 1\ II\ I I \ 1\ I I \ I \J \ ~J \ 
'­
10 12 14 
r 
0.004 
0.000 
6 10 12 14 
Figure 10. R presentati e elution profil of roFab™ . alrox venom reaction 
mixture. Plot A i the profile of roFab™ alone and a mg/mL venom reaction 
mixture. Plot B i the elution profile of reaction mixtur at varying venom 
concentration . Plot B also how the tim point where integration w perform d. 
35
 
2.0 
• Cplx Region 
• roFab Area 
~ CroFab Null 
1.5 • Total Profile Area 
co 
Q) 
<:
l­
t::
 1.0
.2 
Ol)
 
Q)
 
~ 
0.5 
0.0 -.-------.------,----.---------.-----.-­
0.0 0.2 0.4 0.6 0.8 1.0 
Concentration of C. alrox enom m m ) 
Figure J1. Relative peak area normalized to ) mg/m roFab™ at vanou 
concentrations of C. alrox venom. Data point repre nt th m an of an experiment ran 
in duplicat. included are relative peak area expected if no reaction wer to take place 
(null) and data from r action mixture . 
36
 
3.5 Analysis of Cross Reactivity 
Analysis of ero reactivity wa u ed to determine if copperhead venom and 
rattlesnake venom bound to CroFab™ independently (non competitively) or competed 
for binding to CroFab™, The procedure de cribed in Ste ens, t at (23) for epitope 
mapping was modified and used. This procedure u es difference, or delta, profiles to 
determine competitive or noncompetitive binding of antigen with antibodies. Null 
profiles are synthesized by adding the profile of a reaction mixture with the profile of a 
control that had been previously chromatographed (23). Subtracting the null profile from 
that of the reaction profile generates difference profiles. The difference profile are then 
used to determine any changes in reaction mixture. Positive peaks i.n the complex 
region and negative peaks in the CroFab™ and venom region indicated binding has 
occurred. 
Control mixtures containing either CroFab™, copperhead venom or rattlesnake 
venom alone were incubated for I hr at 37° Reaction mixture containing ither 
copperhead venom and antivenin or rattle nake venom and antivenin wer incubated for 
1 hr at 37° C, after which the reaction mixture was divided in half. An additional aliquot 
of either elution buffer or the opposite venom wa added and then incubat d for an 
additional hour. 
Raw data was collected and nonnalized u ing the procedure previou ly described. 
Figure 12 plot A represents the null, reaction mixture, difference profile and a 1 mg/mL 
copperhead venom, for the reaction mixture of antivenin with copperhead venom. The 
null for this profile was constructed by adding together the profiles of CroFab™ and 
copperhead venom controls. The difference profile in this plot is indicative of complex 
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formation with an increa e of compl ar a and a decrea of antiv Gin area. A lading 
peak in the difference profile that i po itiv indicat that additional binding has 
occurred after the initial reaction ha tal< n place. 
Plot B figure 12 repre ent the r action mixture of antivenin and rattle nake 
venom with copperhead venom added after initial incubation. The null was con tructed 
by adding the profile of the reaction mixture for antivenin and rattle nake venom with 
that of the copperhead venom control. E· idence of complex formation is seen in the 
difference profile of increasing complex area and decreasing antivenin area. 
Figure 13 plot A represents the reaction mixture of CroFab™ with rattlesnake 
venom. Included in this plot are profiles for the null, the reaction mixture, a copperhead 
venom control and the difference profile. Plot B of figure 13 shows the profiles of the 
reaction mixture for antivenin and copperhead venom with rattlesnake venom added after 
initial incubation. Both plots are indicative of complex formation with increasing 
compl~x area and decreasing antivenin area. 
Figure 14 compares difference profile. Plot A compare diffi rence profile for 
copperhead venom, the red plot i copperhead only and the blu plot i after the 
introduction of rattlesnake venom. Plot 8 rattlesnake v nom with and without 
copperhead venom. In both instance there eems to be a d crea e in complex area, 
which may indicate that binding of venom to antivenin is not completely independent 
Figure 15 compare the difference profile of an observed reaction mixture containing 
mixture containing CroFab™ + copperhead + rattle nake to that of one expected if 
binding is completely independent. The difference profile indicate that the binding of 
antivenin to venom is not completely independent. The difference between the e two 
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plot indicat that appro imately 15 - 20 % of binding i comp titt . Analy i of the 
data for thi portion of th tudy indicat that th ord r in hich th noms are 
introduced doe not matt r itb the profile being almost identical. All profil ere 
adjusted for injection volume, flow rate and detector r pOD . 
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Figure 12. Repre entative elution profile for reaction mjxture of roFab™ and 
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rattle nake alone, the null profile and the difference profile for the two. Plot B i the 
reaction mixture of roFab™ and copp rh ad enom with rattl nake add dafter th 
initial incubation. Also included are th null and diffi renc profile. Final 
concentration ere I mo mL roFab™ and 0.5 mg/mL venom. 
41
 
0.002 
Plot /-­
I " --- pp rh ad I ft r Initial Incubali n0.001 I pp rh ad Bindin 
I 
I 
/ 
I	 
,.,.--- ­0.000	 ~-~-- ./ /- .",,---'-' 
_/ 
r'­
/ " 
-0.001 f 
I 
I 
I 
I 
I 
\ I(1) -0.002 
'"c::	 'OJ 
o 
~ 
~ 
15 -0.003 
U 6 8 10 12 14 
~ 0.004 
o 
Rattle nake 
0.002 Plot B Rattle nake Sindin ft r Initial Incubation 
0.000 ~/~.",.,,--­
.,.,­
/ 
I 
I
-0.002 I 
I 
I 
\ I 
\ I 
-0.004	 J 
-0.006 
4 6 8 10 12 14 
Tim in Minute 
Figure 14. ompari on of differ nce profile for copperhead and r ttle nake enom. 
Plot A is the difference profiles for copperhead venom. Th red plot i th differenc 
profile for copperh ad venom alone and the blue plot i the differenc for copperhead 
venom after initial binding of rattle nake venom ith antivenin. Plot B i the difti rence 
profile for rattle nake venom. The red plot is tb difference for rattle nak venom alone. 
The blue plot i the differenc aft r initial binding of copperhead venom with antivenin. 
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4.1 Current Treatments 
At pre ent there are only two approved treatment for Crotalinae envenomation in 
the United States, the more traditional ACP and tb new CroFab™. Although the 
indications for the administration of treatment for snake envenomation have not been 
well defined the literature indicates that most common indication appear to be a 
progressive venom injury (4,5,9). Indications such as progres ive welling, clinically 
important coagulation abnormality, or systemic effects uch as hypoten ion, or altered 
mental status lead practitioner to administer treatment. The expected result of treatment 
is the resolution of those symptoms a ociated with the envenomation and tbe prevention 
of further injury as a result of envenomation. 
Each treatment has advantages as well as di advantage. Perhap the most 
important of theses i cost. The more traditional A P h been th main tay of tr atm nt 
in the United States for decades and a such the co t i relatively low, around 650 for a 
kit that contains all components needed for treatment. However, the co t associated with 
CroFab™ is somewhat higher, upward of $1,000 per vial. The COUf e of treatment 
indicated by the product in ert for CroFab™ i an initial do e of 4 to 6 vial. If initial 
control is not achieved the re-admini tration of the initial dose is indicated. After initial 
control is achieved then additional 2 vial dose every 6 hour of up to 18 hour or an 
add.itional 6 vials (1). In a worst-case scenario that could mean up to 18 vials of 
antivenin admini tered which could re ult in a cost nearing $20,000, ju t for antivenin. 
However, the main advantage a ociated with CroFab™ is safety. Although experience 
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with CroFab™ is limited it ha not be n hown to cause anaphylaxi , wherea 
anaphylactic reactions as ociated with th u e of A P are well docum nted 4 9). 
There is one other viable treatment option for copp rhead envenomation. Tbi 
option tres es a conser ativ approach, or one in wbi h i no antivenin is admini teredo 
However, this does not mean a phy ician hould not evaluate the bit ju t that no 
antivenin is administered. In one l2-year study, fifty-five patients of copperhead 
envenomation were succes fully treated con rvatively without the use of antivenin or 
surgical excision (5). Conservative treatments in thi study were administered to all 
patients and included i.v. fluid, tetanus toxoid, teroid and antibiotic. Each individual 
was evaluated and treated by a general surgeon since surgical exci ion i also an option if 
treatment was not progressing as desired (5). 
This method is a result of the copperhead venom being considered as clinically 
benign. As a result of the 12-year study the author recommends that copperhead 
snakebites be categorized separately from other nake envenomation and a con rvative 
approach taken with respect to treatment. However, the author of the tudyaJ 0 goes on 
to state that hould the patient deteriorate at any time a more traditional treatment hould 
be instituted (5). 
The unpredictable nature of snakebite often make a e sment and management 
difficult. The literature can be difficult to interpret because of different methods of 
evaluation, for example the different scoring charts for nake bite severity (Tables 1 and 
2). Also there are no uniform guidelines as to the amount of antivenin that hould be 
administered. As a result some clinicians chao e to treat snakebites without the use of 
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anti enm hile other only u anti nin m mod rat to re n enomations. 
Regardle s of the choice, antivenin i ti 11 th ndard th rapy fi r mo t nak bite . 
4.2 se of Ovine Fab Fragments 
As previou Iy discussed, the u of 0 'ne era to produc Fab fragm nt i not a 
new technique. The introduction of an 0 in Fab fragment in 197] for treatment of 
digoxin poisoning in dogs. With the fir t u e of a digoxin sp cific Fab fragment 
treatment for humans documented in 1976 9-13). In anoth I' report a patient wa 
successfully treated for tricyclic-antidepre ant poisoning u ing an antibody produced 
with ovine sera (26). With the introduction in the United State of roFab™ clinician 
have a choice as to which antivenin to u 
Although today there is only one ovin Fab antivenin treatment approved for 
envenomation of snakes native to North America around the world there are others that 
are available, mostly for envenomation for nakes in Africa and Europ . One of which is 
Ec~iTabTM, manufactured by Therapeutic Antibodi LTD, of Atlanta eorgla. Thi 
antivenin is produced for treatment of Echis 0 'ellatus or carpet vip r nvenomation. Th 
carpet viper is a snake native to Africa, re pon ible for 95% of eriou envenomations in 
Nigeria, with 15 deaths attributed to it each y ar (15). Anoth I' xarnple i Vip raTab , 
which is al 0 manufactured by the maker of 1'0Fab™, i being marked in Europ for 
Vipera berus, or the European common adder, envenomation. An example of an 
antivenin made from ovine Fab fragm n ,which i in the te ting tage, i one for the 
Walterinnesa aegyptia or desert black cobra native to Saudi Arabia. Although thi 
antivenin is not yet in production the re ults from the initial tudy are promi ing. In 
te ting this new antivenin completely neutralized PLA2 activity (24). 
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From the lethality tudie done in mice, roFab™ i approximately 5 time more 
potent than ACP, or in clinical term only one-fLfth a much antivenin i n eded to 
produce the same degree of protection ba ed on the data (1,9 11). The u of purified 
Fab should also negate the immunog nic and allergic properti of intact IgG and its 
corresponding Fc portion. Also other sheep serum component and antibodi that are 
non-specific to the venom are eliminated by the purification step in the production of the 
antivenin. Additionally clinical experience with the antidigitali drug, digoxin, indicates 
the considerable safety of heep Fab products (11). 
Fundamental1y it can be seen that CroFab™ would be more effective with Ie 
adverse side effects than the more traditional ACP. First, venoms from four snake 
native to North America are used in its production, while APi produced from two 
North American and two Central and South American snake. Second, CroFab™ is a 
fragment of an IgO molecule with the Fe portion removed while ACP i an undige ted 
in~ct [gG molecule (11). Lastly, CroFab™ i produced u ing affinity chromatography 
which removes any non-reactive components ver u ACP production may contain non­
reactive IgG molecules. These factor combined should lead to the more wide pread ue 
ofCroFab™ in the future. 
4.3 Relevance for use of SE-HPLC 
SE-HPLC has enabled researchers to carry out peptide purification and analy is of 
peptides up to one hundred times faster than more conventional low-pres ure method 
such as gel filtration (25). The main applications of the technique in relation hip to the 
study of peptides are, purification and analysi of purity, estimation of molecular weight, 
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and the tudy of protein-protein int raction 25). It is prot in-pro in int ractions that 
are rele ant to thi study. 
Since the as ociation of polypeptide with other molecul cause an increa e in 
size, these interaction can be measured by SE-HPLC. bis technique also can provide 
infonnation on the stoichiometry of binding, rat kinetic a ociat d with binding and 
also the distribution of different complexe in th reac ion mixture (23,26). 
Concentration dependant complex formation of multiple form of human CU/Zn oxide 
dismutase, murine monoclonal antibody complexe , a ell as two forms of human 19E 
complexes have been characterized by SE-HPLC (16). Also report d are the formation 
of stable venom-antivenin complexes using SE-HPL (17,18). 
The technique of SE-HPLC has also been u ed ill the identification and 
localization of epitopes on proteins of a known sequence and tructure (23). Stevens et.al 
demonstrated that a reactive Fab fragment in the presence of an antigen with an epitope 
that. has a distinct location will result in the formation of a complex that i of a higher 
molecular weight than that of the antigen and a reacti ve 19 . AI 0 if epitope overlap or 
undergo a conformational change which result in the 10 of an epitope the molecular 
weight of the complex will be lower than expected for independent binding ite (23). 
The technique has also be useful in the determination of the kinetic of binding for Fab 
fragments to antigen epitopes (23,26). 
Antibody-Antigen interaction In mixtures containing reactive and nonreactive 
component using SE-HPLC was modified to fit thi tudy (17). The use of SE-HPLC 
has several favorable characteristics, the reaction occurs in solution, which may limit the 
effect of artifacts associated with protein-protein interactions occurring on the urface of 
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a gel. Condition uch as pH and t mp ratur aT comp r ble to tho type of reaction 
occurring in vivo, and resul that are produced are ea y to int rpret and easily done 
without the use or raidonucleotid ith only the in trumentation found in any a erage 
chromatography laboratory (17). 
These factor lead to the choice of SE-HPL ill thi rudy. For thi tudy to be 
successful a stable high molecular weight compl x formation a required and is indeed 
seen. Figures 8 and II illustrate the do e-re pon e, concentration dependant appearance 
of a high molecular weight complex with corresponding d cr ase in antivenin peak area. 
Figures 7 and 10 how profiles of reaction mixtures of antivenin and venom. The e 
figures are evidence which indicate the formation of a high molecular weight complexe 
with the corresponding decrease in both antivenin and venom components. The e figure 
also relate to objectives 1 and 2, which are I) Determine if a high molecular weight 
complex is fonned and 2) If a complex i formed determine if it i do e dependant. 
4.4 ,Analysis Techn iq ues 
In this study, as with any chromatography elution profil tudy, variable' 
influence the performance of the instrumentation. Factors uch a pH, detector respons , 
and injector malfunction may all I ad to non-ideal elution profi Ie . A such, technique 
must be employed to combat the e variable. For thi tudy analy i of the elution 
profiles tended to be very straightforward and mechani tically easy. How v r, some 
variables were introduced. Because of the sensitivity and inherent background n01 e 
associated with the photodiode array the fir t item corrected for wa baseline by u ing 
oftware from PeakFit (SPSS, Inc., Chicago, IL). Once thi wa aCComplish d the next 
task involved normalization. Normalization allows for comparison of elution profile 
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from the am r action mixtur ran at diffi r nt time. Th or ticall the am reaction 
mjxture will have the ex ct lution profile pro id d all ariable ar equal. Ho er, 
rarely are all variable equal. To account for th diffi r nce in pr file, ar as er 
normalized to 1mg/mL roFab™. Thi normalization allo for the compari on of 
elution profiles of the arne reaction mixture inj ct d at diffi rent time Normalization 
also allow profiles of different concentrati.ons within th data et to b compared on an 
equal basis. Figure 1 relate to the normalization proce . In plot A of this figure it can 
be seen that even after baseline correction the profile are not identical. Plot B of Figure 
I shows that after normalization the elution profile are much more tandardized. The 
same proce S was applied to every elution profile, the information combined and a more 
ideal elution profile was the result. The e new elution profile make the determination 
necessary to answer objectives I and 2 much ea ier. 
The final step of analysis for thi study is integration. For this proce s time point 
wer~ chosen along the X-axi of an lution profil Integration i much more 
straightforward than normalization, however the proce ju t a cruci at to the analy 'i 
of the profile. If the wrong time points are cho en then a problem with area a ociated to 
each portion of the profile may occur. Portions of the profile may have too much area 
as igned to it or not enough. If the region as igned fOf integration i wrong then the 
results will be skewed. 
The scope of thi study allowed for the u e of a microco mputer for data 
acqui ition and feature of software programs uch a Excel to perform int gration. 
Region for integration of chromatograms for thi study were determined by lookjng at 
the elution profile. When a peak is fir t detected that is where integration begin and 
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integration top at the point the peak end. Thi continue until the peaks of int re tare 
all integrated. It i the areas under the pea, which have b en nonnalized and 
integrated, that are of importance to thi.s study. 
4.5 Relevance of Data Obtained 
The EDso for CroFab™ in mice tudie i 4 mg CroFab™/mg copperhead venom 
(1,10). For this study to be lIcces ful, the formation of a stable antivenin-v nom 
complex was needed and is indeed een. For reaction mixtures, concentration dependant 
changes in elution profiles (Figures 7, 10) indicate the formation of table complexes. 
Objective 3 asks that an apparent ECso for CroFab™ be e tabli hed. From the fit of a 
hyperbolic function (Eq. 5) to the data for complex area in Figure 9 and 1I an apparent 
ECso was determined for both copperhead and rartle nake venom. The apparent ECso for 
copperhead venom is 0.05mg venom/mg CroFab™ (R2>.99, p<O.OOI, SE<O.OI), and for 
rattlesnake venom is O.04mg/mL (R2>.98, p<O.005, SE<O.OI). 
To compar the apparent ECso to that of thc repol1ed Dso a linear relation hip 
between ECso and ECloo and between EDso and EDloo was a sumed. The E so is defined 
as the effective concentration of venom where one half of reactive antivenin i bound to 
venom (mg venom / mg CroFab™). The EDso (mg roFab™ / mg venom) i deftn d as 
the concentration of antivenin within a mixture of antivenin and venom that will protect 
50% of the animals tested from death within a given time period (e.g. 48 hr). As 
previoll ly stated the apparent ECso for copperhead venom is 0.05 mg venom I mg 
CroFab™. The reported EDso for copperhead venom is 3.6 mg CroFab / mg venom (I I). 
By using the assumption of linearity, the EClOo and EDlOo for copperhead venom can be 
calculated as 2 x ECso and 2 x EDso respectively. By using this calculation the ECloo for 
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copperhead venom i 0.10 mg venom / mg CroFab™ and the EDIOO i 7.2 mg roFab™ / 
mg venom. For compari on of the E 100 to th EDloo u ing the arne unit (i.e. mg 
venom / mg CroFab™) the reciprocal of EDloo i u ed (I DlOo) which give 0.14 mg 
venom / mg CroFab™ compared to the EC100 of 0.10 mg venom I mg CroFab™. The 
reported EDso for rattlesnake venom i 5.2 mg CroFab™ / mg v nom (11) and the 
apparent ECso is O.()4 mg rattlesnake venom / mg CroFab™. The reciprocal of EDlO(J for 
rattlesnake venom (ED 100 =10.4) is 0.097 mg rattle nake venom / mg CroFab™ which 
compares to the EC lOo of 0.08 mg rattlesnake venom / mg CroFab. 
These results indicate that this method may be valuable in providing an e timate 
of EDso using in vitro estimates of ECso . This estimate would be valuable as a starting 
point in the determination of the actual in vivo EDso. This method, if u ed, could result in 
a significant reduction in cost a sociated with live animal testing 
Objective 5 ask if the antivenin exhibit any cro reactivity between the venoms 
te ~ed. The profiles in Figures 12-15 are u ed to an werthi qu tion. To determine if 
any cross reactivity exists one needs to look at the compari on of d Ita profil in Figure 
15. If there was no cross reactivity between the venoms and roFab M the delta profile 
would be that of independent binding a shown in Figure 15. How ver, Sa ed on the 
data in figure 15 approximately 15-20% of the binding is not independent. 
The intent of this study was to examine the binding of CroFab™ with that of 
copperhead venom. As such the re ult indicate that approximately 30% of CroFab™ is 
reactive and at the EDso 90% of the reactive CroFab™ is bound. Although CroFab™ is 
not produced with copperhead venom, the published data report good ero reactivity 
52
 
with it (I, I0, 11). The data· hown in thi report, for xampl th idence of complex 
fonnation the apparent ECso and delta profile ould t nd to upport thi earlier data. 
4.6 Summary 
Antibody-antigen interaction m nu ture containing r active and nonreactive 
components using SE-HPLC (4) was modified to fit thi tudy. Thi method has vera! 
favorable characteristics. The reaction occur in solution, which may limit 'the number of 
artifacts associated with antigen-antibody interactions occurring on a surface (19). 
Conditions, such as pH and temperature, are comparable to tho e type of reaction 
occurring in vivo. Results produced are asy to interpret and are easily done without the 
use of raidonuc1eotides with only the instrumentation found in the average 
chromatography laboratory (17). Further analy i u ing isolated venom components or 
venoms from other snakes used in the production of CroFab™ could provide more 
insight on the fraction of reactivity and ECso, or even cros -reactivity between other 
venoms or venom component. The method of SE-HPL i applicabl for any y tern in 
which stable complexes are formed. It i the det ction of stable complexe that may be 
relevant to avidity. 
Although results from thi . in vitro study how the total reactive CroFab™ i only 
30% this could be related to effects of antivenin and venom interaction in vivo. These 
interactions in vivo may involve other interactions not directly a sociated with complex 
fonnation or the fonnation of Ie stable complexe not detectable by SE-HPLC. 
Dissociation of Ie s stable complexes may re ult in peak trailing or changes in peak shape 
and elution time of both antivenin and venom. Kinetic rate contributions to simulated 
SE-HPLC elution profiles from protein-protein interaction have been de cribed (] 4,20). 
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Small dissociation rate e.g.::;l 0.2 -I) ould t nd to fa or eparation of bound and free 
components during the chromatographic run, a ould higher flow rate (17). Further, 
ultrafiltration or affmity chromatography may be u d to eparat antiv nin-venom 
complexes and unbound antivenin from both high affinity and low affinity unbound 
antigen in the reaction mixtures (17). Thi method could provide an e tirnate of total 
bound and free antivenin. 
The method of SE-HPLC i simple, fa t, and a ily interpretable it i applicable to 
a variety of systems where protein-protein interaction, which produce stable complexes, 
are studied. Analysis of chromatographic data may provide information about reactive 
an non-reactive components, the magnitude of antibody-antigen interactions including 
estimates of binding parameter, identity of antigenic components, and the relationship 
between antibody-antigen interactions and avidity (17). 
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